Dolat Capital: Dr. Reddy’s Posts In-Line Operational Performance, Expect H2 To Be Subdued
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Dr. Reddy’s Laboratories Ltd. reported a decent Q2 with strong performance in India (Wockhardt portfolio integration and Covid-19 products) and U.S. (new launches).
However, lower export incentive, higher price erosion, change in product mix and adverse currency impacted gross margins (54% in 2Q versus 56% in Q1), in line with estimates.
Adjusting for the impairment charge of Rs 781 million for intangibles, Ebitda margins was in line at 24.3%.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.